NS101
Phase 2Biologic
NS101 is one of 56 biologic programs targeting Frontotemporal Dementia. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
145 competitors in Efficacy
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Tivicay
GSKPhase 3
Rogaine
PfizerPhase 3
Rayos
RRoxane Laboratories
Phase 3
Paraplatin
AAvyxa
Phase 3
Alimta
SShawn Eagle
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Lesinurad
EEsperion Therapeutics, Inc.
Phase 3
Insulin 320
Novo NordiskPhase 3
Pifeltro
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intravenous1 trial
Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NS101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- NNeuracle Science Co., LTD.